Sulfur burps on a GLP-1: what the labels count, what they don't, and the one lever with a number behind it

Two different problems wearing one name

"Sulfur burps" bundles together two things that have different causes, different evidence, and different fixes.

The first is the belching itself — more frequent, more forceful, sometimes dozens of times after a meal. This is in the regulatory record. Every one of the four prescribing documents lists it, under the clinical name eructation, with a rate attached.

The second is the smell — rotten eggs, sulfur, struck matches. This is not in the regulatory record at all. We read all four current prescribing documents from DailyMed, the National Library of Medicine's label repository, on 3 October 2026. Across roughly 900,000 characters, the word "eructation" appears nine times and the word "belching" twice, in the plain-language patient sections. Descriptions of odour: none.

That matters, because it tells you where to look for an answer. The frequency question has a label answer. The smell question does not, and anyone who gives you one is reasoning from physiology rather than reading it off a document.

What the labels count

These are the eructation rates, taken verbatim from section 6.1 of each prescribing information — the adverse-reactions table from the trials the drug was approved on.

Wegovy's pediatric trial reported it separately, at 4% against 0% on placebo.

Two features of that table are worth sitting with.

Only Wegovy and Zepbound list belching among their most common adverse reactions. Each label carries a headline list of reactions occurring in at least 5% of the people studied. Eructation is in Wegovy's and in Zepbound's. It is absent from Ozempic's — which names nausea, vomiting, diarrhea, abdominal pain and constipation — and absent from Mounjaro's.

Ozempic's rate runs backwards. 2.7% at the lower 0.5 mg dose, 1.1% at the higher 1 mg dose. More drug, fewer reports. Mounjaro's is effectively flat across its three doses (3.0%, 2.5%, 3.3%) and Zepbound's nearly so (4%, 5%, 5%). Only Wegovy, at a single reported dose, offers nothing to compare.

The pattern is the licence, not the molecule

Here is the part that explains the table, and it is the same structural fact that governs hair loss on these drugs.

Ozempic and Wegovy are the same molecule, semaglutide. Mounjaro and Zepbound are the same molecule, tirzepatide. Within each pair, the drug itself does not change. Yet within each pair, only one of the two lists belching as a most-common reaction — and it is the weight-management licence both times, never the diabetes one.

The cause is not the drug. It is which trials the label was built from. Ozempic's and Mounjaro's adverse-reaction tables come from trials measuring glycaemic control in people with type 2 diabetes. Wegovy's and Zepbound's come from trials measuring weight reduction, at higher doses, in people losing weight faster. Different populations, different dose ranges, different reporting — same chemistry.

So "does Mounjaro cause fewer burps than Zepbound" is not really answerable from the labels, because the labels were never asking the same question. What you can say is narrower and more useful: a reported rate tells you what happened in that drug's trial programme, not how your molecule behaves. If you are on Mounjaro and belching constantly, Zepbound's 5% describes your molecule at your dose better than Mounjaro's 2.5% does.

Where the smell comes from

The belching is mechanical. Delayed gastric emptying is stated plainly in all four documents — it is why they all carry a warning about anaesthesia and a caution about oral medication absorption. Food sits longer, gas accumulates, and it has one way out.

The smell is microbial, and it is a protein story.

Hydrogen sulfide is the gas responsible for the rotten-egg character. Gut bacteria generate it from sulfur-containing amino acids — principally cysteine and methionine — which are concentrated in protein-rich foods: eggs, meat, dairy, whey, cruciferous vegetables, garlic and onion.

How much difference does that make? A 2018 study in Gut Microbes measured it directly, incubating human faecal samples and sampling the gas every five minutes over four hours. Adding cysteine raised hydrogen sulfide production by 1,557% against unspiked controls. Adding inorganic sulfate, by contrast, had minimal effect.

That distinction is the useful part: it is the sulfur in amino acids that drives the gas, not sulfur in general. And it explains why the problem shows up when it does. A longer gastric and intestinal transit time gives bacteria more hours with the same protein, and on a GLP-1 the standard nutrition advice is to prioritise protein. The mechanism and the dietary advice point the same direction.

The fibre finding that inverts the usual advice

The same study tested whether anything suppressed it. This is where the result gets genuinely counterintuitive:

Readily fermentable fibres cut production by roughly 80–90%. Minimally fermentable ones barely moved it.

Psyllium is the fibre most commonly recommended for GLP-1 digestive complaints. It is the active ingredient in the bulk-forming supplements that get suggested for constipation, and it is in the under-35% group here. The last row is the most practical one: fermentable fibre suppressed the gas by 90% even when cysteine was present — meaning it worked alongside the protein rather than requiring less of it.

Resistant starch and fructo-oligosaccharides are not supplement names. They are in cooked-and-cooled potatoes and rice, slightly green bananas, cooked-and-cooled oats, legumes, onion, garlic, asparagus and leek.

Two honest limits on this. It was measured in vitro, in faecal slurries, not in people, and not in anyone taking a GLP-1 — so the effect sizes describe a laboratory system, not a predicted outcome for you. And some of those same foods are FODMAP-rich, which for a subset of people trades one gas problem for another. No label mentions fibre in this context at all.

Why it usually fades — and which labels will tell you so

This is a real per-drug difference, and it is in the documents.

Both tirzepatide labels state it outright in section 12.2:

Tirzepatide delays gastric emptying. The delay is largest after the first dose and this effect diminishes over time.

The semaglutide labels say only "Semaglutide delays gastric emptying," with no statement about time course.

The research fills that gap, and in the same direction. A phase 1 study published in Diabetes, Obesity and Metabolism found tirzepatide's effect on gastric emptying, measured by acetaminophen absorption, diminished after multiple doses in healthy participants — though a residual delay persisted in participants with type 2 diabetes who were still stepping their dose upward. A separate randomized trial of semaglutide 2.4 mg in 72 adults with obesity found no evidence of delayed gastric emptying at week 20: the primary measure rose 8%, and that difference lost significance once corrected for weight loss.

So the mechanism driving the belching is strongest early and weaker later. Wegovy's label says the same thing from the adverse-event side — of a list that explicitly includes eructation, it notes: "These reactions were most frequently reported during dosage escalation."

If you are in your first weeks or have just stepped up a dose, the evidence says this is the worst it will be.

What to do without giving up your protein

This site's position on protein is not subtle: protein is how you keep muscle while losing weight fast, and the research on how much you need points higher than most people eat. Nothing above changes that. Cutting protein to stop burping trades a smell for lean mass, which is a bad trade.

What the evidence actually supports:

• Spread the same protein across more meals. Total protein is what protects muscle; the load arriving at once is what sits in a slow stomach. Four moderate servings are not the same experience as two large ones, at identical daily grams. The protein calculator gives you your daily number; splitting it is free.
• Pair protein with fermentable fibre rather than cutting it. This is the one lever with a measured effect size, and the 90% figure came from a condition where cysteine was still present.
• Expect the worst of it during titration, because both tirzepatide labels and the semaglutide trial data say the delay itself is front-loaded.
• Reconsider psyllium specifically if you are taking it for this. It is well evidenced for constipation and poorly evidenced for sulfide.
• Note what else slows the stomach. Alcohol's absorption is affected by the same delay — we covered what the labels do and don't say about drinking separately.

Your drug's own side-effect page has the rest of its GI profile: Ozempic, Wegovy, Mounjaro and Zepbound.

When it isn't just burps

Belching is unpleasant and not dangerous. Some things that accompany it are.

All four labels carry warnings for acute pancreatitis and for gallbladder disease, and both can present with upper abdominal pain. Persistent vomiting, severe or radiating abdominal pain, inability to keep fluids down, or signs of dehydration are reasons to contact your prescriber rather than adjust your diet. Each label also warns that these drugs delay gastric emptying ahead of general anaesthesia or deep sedation — tell any clinician planning a procedure that you take one.

Nothing on this page is a reason to change your dose. That conversation belongs with whoever prescribed it.

Sources

• Ozempic prescribing information, section 6.1 — DailyMed
• Wegovy prescribing information, sections 6.1 and 12.2 — DailyMed
• Mounjaro prescribing information, sections 6.1 and 12.2 — DailyMed
• Zepbound prescribing information, sections 6.1 and 12.2 — DailyMed
• Yao CK, Rotbart A, Ou JZ, Kalantar-Zadeh K, Muir JG, Gibson PR. Modulation of colonic hydrogen sulfide production by diet and mesalazine utilizing a novel gas-profiling technology. Gut Microbes. 2018;9(6):510–522 — PubMed 29561196
• Urva S, Coskun T, Loghin C, et al. The novel dual GIP and GLP-1 receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes, Obesity and Metabolism. 2020;22(10):1886–1891 — PubMed 32519795
• Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021;23(3):754–762 — PubMed 33269530
• Jalleh RJ, Rayner CK, Hausken T, Jones KL, Camilleri M, Horowitz M. Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions. Lancet Gastroenterology & Hepatology. 2024;9(10):957–964 — PubMed 39096914

MALAI is not affiliated with Novo Nordisk or Eli Lilly. Ozempic and Wegovy are trademarks of Novo Nordisk; Mounjaro and Zepbound are trademarks of Eli Lilly and Company. This page is nutrition information, not medical advice.